Share Name Share Symbol Market Type Share ISIN Share Description
Akers Biosciences, Inc LSE:AKR London Ordinary Share US00973E1029 COM SHS NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 56.00p 52.00p 60.00p 56.00p 56.00p 56.00p 32 07:55:37
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 2.4 -2.7 -49.4 - 5.56

Akers Biosciences (AKR) Latest News

More Akers Biosciences News
Akers Biosciences Takeover Rumours

Akers Biosciences (AKR) Share Charts

1 Year Akers Biosciences Chart

1 Year Akers Biosciences Chart

1 Month Akers Biosciences Chart

1 Month Akers Biosciences Chart

Intraday Akers Biosciences Chart

Intraday Akers Biosciences Chart

Akers Biosciences (AKR) Discussions and Chat

Akers Biosciences Forums and Chat

Date Time Title Posts
23/11/201700:24Akers Biosciences Inc 20113,582
24/8/201507:47Akers biosciences229
05/9/201412:48Reasons to BUY in Akers Bioscience (AKR)-
01/9/201319:40FDR Aprrobval due to today4
14/1/201100:33Akers Biosciences Inc - 2010 Thread54

Add a New Thread

Akers Biosciences (AKR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
10:26:3157.003218.24O
View all Akers Biosciences trades in real-time

Akers Biosciences (AKR) Top Chat Posts

DateSubject
23/11/2017
08:20
Akers Biosciences Daily Update: Akers Biosciences, Inc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker AKR. The last closing price for Akers Biosciences was 56p.
Akers Biosciences, Inc has a 4 week average price of 56p and a 12 week average price of 56p.
The 1 year high share price is 245p while the 1 year low share price is currently 56p.
There are currently 9,920,552 shares in issue and the average daily traded volume is 1,154 shares. The market capitalisation of Akers Biosciences, Inc is £5,555,509.12.
20/4/2017
09:47
money maker1: I think this could be a 15 bagger within 8 months. ImmuPharma (IMM) Share price 55.6p Market Cap £73m 1) ‘Lupuzor’; for Lupus currently in pivotal Phase 3 trials. 2) All patients now recruited. 3) Results expected Q1 2018. 4) Incremental announcements expected throughout 2017. 5) On FDA’s “fast track” “special protocol” route after strong safety and efficacy in Phase 2, so if IMM adheres to same protocol as Phase 2b and delivers positive results, FDA will approve and not request further trial with different endpoints or outcomes. 6) Potential “multi-billion dollar sales”. 7) Currently 100% owned by IMM. 8) Very little competition, with only one other Lupus drug approved in last 50 years - GSK’s Benlysta reached sales over $400m in 2015, with annual sales predicted at $1bn by 2020. 9) IMM’s Lupuzor already demonstrated in Phase IIb to be safer and more effective than Benlysta, and is expected to have lower pricing. 10) Fully cashed up from £4.1m fund raise in March 2017, enabling it to complete pivotal Phase 3 trials and progress other pipeline projects. Northland Capital has 171p current valuation on IMM. With the blockbuster sales potential, little competition, good Phase 2 and FDA fast track and special protocol status, I personally think it could be £7 to £10 if the Phase 3 results are good in Q1 2018. ----------------------- 14/3/2017 "There's going to be a fantastic return on investment for anybody who invests in ImmuPharma...This is going to be a multi-billion dollar drug, its as simple as that...This will absolutely be a multi-billion dollar drug" [i.e. IMM’s Lupuzor] 4 min 40 sec. www.youtube.com/watch?v=M5Af_uSSXTM www.immupharma.org/sites/default/modules/immu/downloads/IMM-presentation-march-2017v2.pdf
13/4/2017
08:59
wigwammer: Re post 3476.I'm sure there was no relationship between the $2m china order not materialising (equiv toaround 70% of 2016 sales) and the declining share price.Good point. Well made.
28/3/2017
20:29
mcmather: From the original RNS 1 Dec 2016: Walt - "We developed the only test marketed in the USA with the capacity to achieve this and we believe that is why First Check - a major force in rapid diagnostics - has chosen to start selling our test through their popular brand. We hope this is the start of a mutually beneficial relationship between First Check and Akers Bio which could even expand beyond cholesterol and into other areas of rapid testing." According the United States Centers for Disease Control and Prevention, 73.5 million adults (31.7%) in the United States have high 'bad cholesterol' and fewer than 1 in every 3 of them has the condition under control. hTtp://uk.advfn.com/stock-market/london/akers-biosciences-AKR/share-news/Akers-Biosciences-Inc-US-Distribution-Agreement/73039550 Tend to agree Norbus - there are similar kind of products in the UK but I doubt that I'd ever buy one. The US though might be interesting; if 10% of the 73.5m US adults alluded to undertook a disposal test and, say, once a month that would loosely equate to 100m tests a year (averaged up). Even if they just got a very small piece of that action it would likely have an impact here. Bit more research to follow:
10/1/2017
09:01
mcmather: The initial S3 form included the comment: "...and a per share price of $3.30 based on the closing sale price of our common stock on October 18, 2016". The price of $1.20 with warrants at $1.50 suggests to me either gross incompetence or, as you say Norbus, no confidence in the company and the management. Or perhaps both.
02/12/2016
12:40
ramridge: wigwammer - Here is an extract from yesterday's RNS " Akers Bio's Tri-Cholesterol "Check" test is the only combined rapid test which provides an estimate of a person's Total cholesterol as well as their High Density Lipoprotein ("HDL") cholesterol levels - their 'good cholesterol'; thereby providing an estimate of a person's Low Density Lipoprotein ("LDL") levels - their 'bad cholesterol'. These features are essential to accurately differentiating between a person's 'good' and 'bad' cholesterol thereby making it a truly effective screening test for high cholesterol. " Well, that is a blatant lie. It is not the only such product in the market. A few minutes of googling providing me with information about quite a few others in the market able to analyse to the same degree. Below is just one example: " Cholesterol Home Test: The one name that comes up most often for home cholesterol tests is CardioChek. They have the more scientific looking devices that sell for over $100 and promise clinically accurate results. Their blood analyzers do score better in tests than the less expensive paper strips without an electronic device to analyze them. The top rated CardioChek Home Blood Analyzer # 730, 1 ea is one that we found listed all over the Internet. Not all owner reviews are positive, but it did more praise than other systems. The device uses color coded PTS PANELS test strips that get inserted into the machine and you get a readout for Total Cholesterol, HDL Cholesterol, Triglycerides, Glucose and Ketone. The digital display will give you the details usually after 1 to 2 minutes of analysis. You get 2 test strips in the package along with 2 AAA batteries that it requires to run. " My point is this. As a result of management putting out this blatant lie (at best management is incompetent if they were not aware of such competing products, or at worse deliberately misleading the public), the share price spiked yesterday to as much as 255p before crashing. Go tell the guys who bought on the news that this is not important but HIT, etc is . This is misleading the market in a serious way that should not go unpunished.
15/11/2016
12:12
rivaldo: No callers eh - that's what you call "under the radar" :o)) They definitively say that Q4 "is expected to be profitable", and that the rest of the $2.5m Chinese order will be received this quarter. So these things had better happen. I suspect when/if they announce the receipt of the Chinese cash the share price may go a fair bit higher. Here's a link to the conference call for the record: Http://seekingalpha.com/article/4023217-akers-biosciences-aker-ceo-john-gormally-q3-2016-results-earnings-call-transcript?part=single
18/8/2015
08:13
mcmather: 9 January 2015 - For services rendered and to be rendered to the Company the following receive: Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75) Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75) Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75) Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75) Raymond F. Akers Jr., Ph.D. Total Calculated Compensation $381,473 As of Fiscal Year 2013 hTTp://www.bloomberg.com/research/stocks/people/person.asp?personId=6995887&ticker=AKR:LN
05/8/2015
21:44
mcmather: Depends whether you are including the below in the "us" bit? 9 January 2015 - For services rendered and to be rendered to the Company the following receive: Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75) Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75) Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75) Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75) Raymond F. Akers Jr., Ph.D. Total Calculated Compensation $381,473 As of Fiscal Year 2013 hTTp://www.bloomberg.com/research/stocks/people/person.asp?personId=6995887&ticker=AKR:LN Good luck wolfie and waylander by the way.
16/7/2015
22:34
mcmather: This from around 2008/09: Rep. Rob Andrews (NJ-1) requests $20,000,000 for: Akers Biosciences Inc. 201 Grove Road Thorofare, NJ 08086. hTtps://washingtonwatch.com/bills/show/ED_8072.html This from 30 June 2015: In addition, Mr. Andrews was appointed to the Company's Governance and Nominating Committee, Compensation Committee and Audit Committee; and will serve as the Chairman of the Company's Compensation Committee. Anyone guess where this is going?? This from the heading: 9 January 2015 - Greedy incompetents or citizens the US should be rightly proud of? Discussion welcome on the thread. 23 July 2013 - Dr Raymond Akers disposes of 7m shares; roughly £140,000. 8 August 2013 - Proposed Nasdaq listing. 18 November 2013 - Share consolidation; 156/1. 23 January 2014 - Listing opens on Nasdaq. 14 May 2014 - Q1 2014 results - Net loss $595,600 mainly due to costs associated with NASDAQ IPO. 12 August 2014 - Q2 2014 results - Net loss $494,995 Three factors contributed to the increased loss: maintaining dual listings of our stock has significantly increased costs associated with compliance with regulatory requirements, the expansion of sales and marketing efforts and stock option based compensation for our directors, officers and key employees. 13 November 2014 - Q3 2014 results - Net loss $1,124,320 as a result of hiring additional personnel, capital market commitments and marketing activities. 9 January 2015 - For services rendered and to be rendered to the Company the following receive: Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75) Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75) Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75) Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75) Raymond F. Akers Jr., Ph.D. Total Calculated Compensation $381,473 As of Fiscal Year 2013 hTTp://www.bloomberg.com/research/stocks/people/person.asp?personId=6995887&ticker=AKR:LN
09/3/2015
17:56
mcmather: Norbus, re Dr Raymond Akers Jnr's 'activities' here, I'd suspect that there are one or two - perhaps quite a few more? - paying close attention to all ongoing including this from an earlier post on here: $650,000 for a company which will later announce massive losses for 2014; his remuneration package will equate to around 14.5% of all (gross, not net) revenue generated by the company in 2014. As the heading asks: 9 January 2015 - Greedy incompetents or citizens the US should be rightly proud of? Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75) Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75) Gavin Moran 35,000 shares = $131,250 (based on a share price of $3.75) Brandon Thomas Knox 25,000 shares = $93,750 (based on a share price of $3.75) The Mail Online appears to have 100m unique hits / visitors per month and this fella tipped them as his share for 2015: Ian Lyall - Akers Bioscience If you look at the share price chart of Akers Bioscience you’d think it hadn’t been a particularly clever year for the diagnostics company. http://www.thisismoney.co.uk/money/investing/article-2890431/Shares-vote-2015-Daily-Mail-s-City-reporters-reveal-market-tips.html#ixzz3Tubf4INL
Akers Biosciences share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20171123 20:45:41